Focus: Sagent Pharmaceuticals is a specialty pharmaceutical company focused on injectable small molecules, headquartered in Schaumburg, IL. The company operates a mature portfolio of generic and branded injectables with significant concentration in antibiotic and supportive care products.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Sagent is a stable, commercial-stage specialty pharma with low innovation risk but limited scientific upside—best for sales, operations, and regulatory professionals seeking mature-market expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Primary revenue driver (56% of revenue); branded NDA product at market peak supporting commercial organization.
Help build intelligence for Sagent Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sagent Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary revenue contributor; generic ANDA product in mature market phase.
Generic version of lead product; reflects competitive generic market dynamics.
Mature supportive care injectable with minimal differentiation.
Niche perioperative injectable with limited revenue visibility.
Commodity anticoagulant in highly competitive generic space.
Oncology supportive care product with specialized indication set.
Oncology chemotherapy generic with established but erosive market position.
Neonatal specialty product with limited patient population but defensible market.
Generic antibiotic in competitive infection treatment space.
23 discontinued, 61 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+64 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo